Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Prelude Dx
PreludeDx™ Achieves New Milestones for DCIS Patients and DCISionRT® Testing
Newswise — LAGUNA HILLS, Calif., June 12, 2026 -- Prelude Corporation (PreludeDx™), a leader in precision diagnostics for breast cancer, today highlighted a new milestone for DCISionRT®, its validated genomic test that provides individualized recurrence risk assessment and predicts radiation therapy benefit for women diagnosed with ductal carcinoma in situ (DCIS). Approximately 60,000 women are diagnosed with DCIS in the United States each year.
PreludeDx Announces Publication in Breast Cancer Research Validating AidaBreast™, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer
, /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, announced today the publication of results from a large, multi-institutional validation study of the AidaBreast™ test in Breast Cancer Research. The groundbreaking data demonstrated the test to be both prognostic for 10-year recurrence risk and predictive for radiation therapy benefit.
PreludeDx Announces First Independent Validation of AidaBreast™, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer
, /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced results from the first independent validation of AidaBreast™, a novel multi-omic biosignature developed to predict a woman’s 10-year risk of locoregional recurrence (LRR) and her individualized benefit from adjuvant radiation therapy (RT) following breast-conserving surgery.
PreludeDx Study Demonstrates Superiority of DCISionRT® Over Clinicopathology Factors and Criteria for DCIS Treatment Management
Newswise — LAGUNA HILLS, Calif., July 31, 2025 /PRNewswire/ -- PreludeDx™, a leader in breast cancer precision diagnostics, today announced the publication of new groundbreaking data in the International Journal of Radiation Oncology• Biology• Physics ("Red Journal"). The study demonstrated that clinicopathology (CP) based risk assessment frequently fails to accurately assess recurrence risk and radiation therapy benefit for patients diagnosed with DCIS.
PreludeDx Receives FDA Breakthrough Device Designation for DCISionRT® Test for DCIS Breast Cancer Patients
PreludeDx Receives FDA Breakthrough Device Designation for DCISionRT® Test for DCIS Breast Cancer Patients News provided by PreludeDx Jan 16, 2025, 7:00 AM ET , /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation for its DCISionRT® test.
PreludeDx Receives FDA Breakthrough Device Designation for DCISionRT® Test for DCIS Breast Cancer Patients
, /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation for its DCISionRT® test. DCISionRT provides individualized risk assessment and predicts the benefit of radiation therapy (RT) for women diagnosed with ductal carcinoma in situ (DCIS), also known as Stage 0 breast cancer.
PreludeDx Announces Groundbreaking Study Results on HER2-Positive DCIS Patients
PreludeDx Announces Groundbreaking Study Results on HER2-Positive DCIS Patients News provided by PreludeDx Oct 02, 2024, 7:00 AM ET , /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced results of a cutting-edge study in Clinical Breast Cancer. The study, marks a significant advancement in personalized treatment for DCIS patients.
PreludeDx™ and Cancer Help Desk Announce Collaboration to Support Women Diagnosed with DCIS Breast Cancer
, /PRNewswire/ -- Prelude Corporation (PreludeDx™) a breast cancer precision diagnostics company, and Cancer Help Desk, have partnered to provide expert nurse navigation services for women diagnosed with ductal carcinoma in situ (DCIS) breast cancer. This alliance allows for direct engagement between newly diagnosed DCIS patients seeking assistance with clinical options and healthcare professionals trained in breast cancer patient navigation.
The DCISionRT® Test Result is the Most Important Factor Determining Clinician Treatment Recommendations - Findings from Multicenter PREDICT Study of 2,007 Patients
The DCISionRT® Test Result is the Most Important Factor Determining Clinician Treatment Recommendations - Findings from Multicenter PREDICT Study of 2,007 Patients News provided by PreludeDx Jun 26, 2024, 7:00 AM ET , /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, announced an important advancement in the field of breast cancer care with the publication of the PREDICT study in the Annals of Surgical Oncology (ASO). This...
PreludeDx Presents New Data Highlighting Ability of DCISionRT® to Predict Benefit of Radiation Therapy in DCIS Patients, Independent of Endocrine Therapy (ET)
, /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced that it will share data demonstrating the power of its DCISionRT® test to better predict radiation therapy (RT) benefit in comparison to clinicopathologic risk factors for women with ductal carcinoma in situ (DCIS) at The American Society of Clinical Oncology (ASCO), to be held on May 31 – June 4, 2024 at the McCormick Place in Chicago.
PreludeDx Welcomes Dr. Pat Whitworth as Chief Medical Officer to Drive Expansion of Precision Diagnostics
PreludeDx Welcomes Dr. Pat Whitworth as Chief Medical Officer to Drive Expansion of Precision Diagnostics News provided by PreludeDx May 02, 2024, 7:00 AM ET , /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, announced the appointment of Dr. Pat Whitworth as its new Chief Medical Officer.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Prelude
Contact Prelude, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack